April 30, 2025 07:37 AM EDTUpdated 09:45 AM
Deals
Pharma

Up­dat­ed: No­var­tis to buy Reg­u­lus Ther­a­peu­tics for up to $1.7B

Elizabeth Cairns

Senior biopharma journalist

Kyle LaHucik

Senior Reporter

No­var­tis plans to ac­quire Reg­u­lus Ther­a­peu­tics for $7.00 per share in cash, or $800 mil­lion, the mi­croR­NA spe­cial­ist said Wednes­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves J&J's rare dis­ease drug that's ex­pect­ed to com­pete with ar­genx and UCB

Sci­en­tists alarmed about fu­ture of can­cer re­search; TIG­IT, CAR-NK and more from #AACR25

The End­points Slack in­ter­view: Arc In­sti­tute's Patrick Hsu on in­vest­ing, AI and new ways of re­search

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

FDA won't re­or­ga­nize med­ical prod­uct cen­ters, Makary says in in­ter­view: 'I re­ject­ed that pro­pos­al'

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times